GET NOTIFIED



HAVN LIFE SCIENCES SIGNS SUPPLY AGREEMENT WITH MYCOTOPIA THERAPIES

HAVN LIFE SIGNS AGREEMENT TO SUPPLY PSILOCYBIN FOR MYCOTOPIA THERAPIES

Press Releases / August 25, 2021

The partnership will further industry growth for naturally derived psilocybin

Vancouver, BC – Havn Life Sciences Inc. (CSE: <u>HAVN</u>) (OTC: <u>HAVLF</u>) (FSE: <u>5NP</u>) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, recently signed an agreement to supply naturally-derived psilocybin to Mycotopia Therapies (OTC: TPIA) for their psychedelic therapies.

Headquartered in Florida, Mycotopia Therapies uses psilocybin to treat people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions. Their approach is technology-focused, data-driven, and utilizes medical-based solutions as part of their therapies. They aim to help individuals heal and reclaim their life, and endeavor to guide individuals through a journey of healing.

In addition to their work around psychedelic therapies, they're also exploring the different ways in which psychedelics can be ingested for treatment through inhalers, vaporizers, topical methods, tinctures, ingestible capsules, and edibles.

"HAVN Life and Mycotopia Therapies are a natural fit as partners; both companies share a researchbased approach to psilocybin and a deep dedication to bettering human health," says HAVN Life CEO, Tim Moore. "This new partnership advances our efforts to supply safe, quality controlled psilocybin medicine to researchers and patients around the globe. We're thrilled our partner Hypha Wellness was able to introduce us to Mycotopia Therapies and facilitate a successful agreement."

The psilocybin provided to Mycotopia Therapies will come from HAVN Labs' Jamaican facility, where it works directly with Hypha Wellness to produce regulated medical psilocybin. The partnership between HAVN Life and Hypha Wellness was finalized in March 2021 and allows HAVN to optimize and refine their distribution and efficiency.

On Behalf of The Board of Directors

Tim Moore Chief Executive Officer

About HAVN Life Sciences Inc.

<u>HAVN Life Sciences</u> is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at <u>yourhavnlife.com</u>, and follow us on <u>Facebook</u>, <u>Twitter</u>, <u>Instagram</u> and <u>Youtube</u>.

About Mycotopia Therapies

Mycotopia Therapies Inc. provides psychedelic therapies through technology-focused, data-driven, and medical-based solutions for people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions. With a primary focus of helping you heal and reclaim your life, Mycotopia Therapy endeavors to guide individuals through their journey of healing. This is accomplished by acquiring an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. The company operates as a subsidiary of EHAVE, Inc. Additional information on Mycotopia Therapy can be found on the Company's website at: <u>https://www.mycotopiatherapies.com</u>

Connect

Investor Relations ir@havnlife.com (604) 687-7130 Facebook: <u>@havnlife</u> Twitter: <u>@havnlife</u> Insta: <u>@havn.life</u> LinkedIn: <u>@Havn Life</u> Youtube: <u>@HavnLife</u> Media Contact savi@emergence-creative.com (647) 896-8078

<u>← Previous Post</u>

Leave a Comment

Your email address will not be published. Required fields are marked *

Type here..

Name*

E	r	L	٦	а	i	I	*

Website

□ Save my name, email, and website in this browser for the next time I comment.

POST COMMENT »

Search ...

Recent Posts

HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies

Harvard Law's Petrie-Flom Center Announces Project on Psychedelics Law and Regulation

New Potential for Psychedelics in Stroke Recovery

HAVN Life Sciences TO Present at Q3 Investor Summit Virtual Conference

HAVN Life Harvests First Crop of Psilocybin Mushrooms at its Jamaica Facility

Categories

Education

Health & Performance

Plant Medicines

Press Releases

Psychedelics

ABOUT	WHAT WE DO
Our Story	HAVN Labs
Mission	HAVN Retail

NEWS

Team

INVESTORS

CONTACT

EDUCATION

PRESENTATION DOWNLOAD



SUBSCRIBE

Sign up to receive our latest news and updates!

YOUR EMAIL

SIGN UP

Disclaimer Privacy